Clinical trials recruiting for Castration Resistant Prostatic Cancer
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 3 |
| New York | 3 |
| Michigan | 2 |
| Pennsylvania | 2 |
| Tennessee | 2 |
| Texas | 2 |
| Alabama | 1 |
| Arizona | 1 |
| Connecticut | 1 |
| District of Columbia | 1 |
| Florida | 1 |
| Illinois | 1 |
Top cities
Self-screener
Recruiting trials
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Study of MGC026 in Participants With Advanced Solid Tumors
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
- Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
Related conditions
Trials recruiting for Castration Resistant Prostatic Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Castration Resistant Prostatic Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.